Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02547402 · ClinicalTrials.gov registry record · Phase 1

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

A Phase 1 study of Acute Kidney Injury, sponsored by Complexa.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT02547402 is a Phase 1 study of Acute Kidney Injury that has completed, run by Complexa. The registered enrollment target is 10 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02547402, a Phase 1 study of Acute Kidney Injury, has completed, sponsored by Complexa.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This is an exploratory study in a small, well controlled group of healthy subjects to explore the effect of CXA-10 on pravastatin and Vytorin® (combination of simvastatin and ezetimibe).

Conditions Studied

Interventions

  • DRUG CXA-10
  • DRUG pravastatin
  • DRUG Vytorin® (combination of simvastatin and ezetimibe)

Study Locations (1)

Michigan

  • Jasper Clinical Research & Development, Inc. - Kalamazoo

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-12
Est. Completion 2016-02
Phase Phase 1

Sponsor

Complexa

8 total trials

What the Registry Record Tells You About NCT02547402

The ClinicalTrials.gov registry entry for NCT02547402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (100% lower). The listed sponsor is Complexa, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 3 interventions - of which CXA-10 is the first listed.

NCT02547402 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02547402 about?

NCT02547402 is a clinical study titled "A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males". This is an exploratory study in a small, well controlled group of healthy subjects to explore the effect of CXA-10 on pravastatin and Vytorin® (combination of simvastatin and ezetimibe).

What is the current status of trial NCT02547402?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-12. Estimated completion is 2016-02.

What conditions does trial NCT02547402 study?

This clinical trial studies the following conditions: Acute Kidney Injury.

What interventions are being tested in trial NCT02547402?

The interventions under investigation include: CXA-10 (DRUG), pravastatin (DRUG), Vytorin® (combination of simvastatin and ezetimibe) (DRUG).

Who is sponsoring clinical trial NCT02547402?

This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02547402 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Kidney Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.